Prescribed by a Clinician, Supplied by a Pharmacy: How Wegovy Works in the UK

Wegovy contains semaglutide, a GLP-1 receptor agonist made by Novo Nordisk — it works by mimicking a gut hormone that regulates appetite and slows the speed at which the stomach empties.
UK licence covers adults with a BMI of 30 or above, or 27 and above when a weight-related condition such as high blood pressure or type 2 diabetes is present.
Clinical trials (STEP 1, 68 weeks) showed an average body-weight reduction of around 15% at the 2.4 mg maintenance dose; a newer 7.2 mg dose, approved by the MHRA in April 2026, showed approximately 20.7% average loss.
Wegovy is a Black Triangle (▼) medicine, meaning the MHRA keeps it under additional monitoring, reporting any suspected side effects via the Yellow Card scheme helps build the safety record.

Wegovy is a once-weekly injection containing semaglutide, licensed in the UK for weight management in adults. It is a prescription-only medicine, which means it can only be supplied after a qualified prescriber has assessed whether it is clinically suitable for you — not purchased freely like an over-the-counter product. If you have seen it referred to online as something you can simply pick up, that framing misses a critical step. Every legitimate supply of Wegovy in the UK begins with a clinical consultation, a prescriber's decision, and a pharmacy that holds the correct regulatory authorisations to dispense it.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Everything a first-time reader should know before taking Wegovy further

What actually happens when you start Wegovy?

Semaglutide works on the GLP-1 receptors found in the brain's appetite centres and in the gut. By activating those receptors, the medicine dampens hunger signals and slows gastric emptying, so food sits in the stomach longer and feelings of fullness arrive sooner and last longer. The result, for most people, is a natural reduction in how much they eat rather than a forced restriction.

Treatment does not begin at full strength. The prescriber-led schedule starts at 0.25 mg weekly, stepping up roughly every four weeks through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose. That gradual climb exists to let the body adjust and to keep gastrointestinal side effects manageable. Nausea, loose stools and indigestion are the most commonly reported reactions, and they tend to be most noticeable in the first week or two after each increase, then settle. The NHS patient page on semaglutide sets out the full side-effect profile in plain language and is worth bookmarking before you start.

The April 2026 MHRA approval of a dedicated 7.2 mg single-dose pen extended the ceiling for people who tolerate the earlier doses well. That higher dose approaches the weight-loss figures seen with tirzepatide in head-to-head data. Whether it is suitable depends on how you respond to treatment, a conversation for you and your prescriber, not a default target.

You can read more about how the weekly injection schedule unfolds in practice on our Wegovy day-by-day guide.

Who can be prescribed Wegovy in the UK, and who decides?

The licensed eligibility criteria are set by the medicine's authorisation, not by any individual clinic. For weight management, Wegovy is licensed for adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition, things like hypertension, dyslipidaemia, obstructive sleep apnoea, prediabetes or type 2 diabetes. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance.

Meeting those numbers is the starting point, not the end of the assessment. A prescriber also considers your medical history, any medicines you already take, and whether there are reasons Wegovy would not be appropriate, for example, a personal or family history of medullary thyroid carcinoma, certain gastrointestinal conditions, or a current pregnancy. Wegovy is not recommended during pregnancy, breastfeeding or when trying to conceive, and it is not licensed for anyone under 18.

The prescriber's role is to weigh all of that up individually. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the day it is submitted. There is no algorithm making that call. You can see how our clinical team approaches that process on the clinical team page.

NICE has also published formal recommendations on semaglutide for weight management (TA875), which set out the conditions under which it is recommended within NHS specialist services. If you are exploring the full range of treatment options, understanding both the NHS and private routes is useful context.

Is Wegovy available on the NHS, and what does that mean for private supply?

Wegovy is available on the NHS, but access is strictly conditional. NICE guidance TA875 recommends it only within specialist weight management services, for a maximum of two years, and for adults who meet specific BMI and comorbidity thresholds. Waiting lists for those services are often long, and the pathway requires multidisciplinary support alongside the medicine itself.

For people who do not meet the NHS criteria, or who cannot wait, a private prescription from a regulated online pharmacy is the legal alternative. The same prescription requirement applies, a private clinician still needs to assess suitability before any medicine is dispensed. The difference is speed and eligibility threshold, not the clinical process itself.

One habit worth building before you use any online pharmacy: spend thirty seconds checking it on the GPhC pharmacy register. Legitimate UK pharmacies hold a GPhC premises registration you can verify publicly. nume's registration number is 9012878. If you are also curious about who manufactures Wegovy and how it is produced, that background can help you spot fakes more confidently. Sellers offering Wegovy without requiring a clinical assessment, or at prices that seem implausibly low, are red flags the MHRA has warned about repeatedly, counterfeit pens have been seized in large numbers across the UK.

Our guide to getting Wegovy online safely covers what to look for in more detail, including the specific questions worth asking any provider before you commit.

What should you realistically expect from Wegovy over time?

Clinical trial results give a useful benchmark, with the honest caveat that individual responses vary. In STEP 1, adults using the 2.4 mg dose alongside lifestyle changes lost an average of around 15% of body weight over 68 weeks, compared with roughly 2.4% in the placebo group, figures published in the New England Journal of Medicine. The newer 7.2 mg data, from trials supporting the April 2026 MHRA approval, reported approximately 20.7% average loss.

Those are averages across large populations. Some people lose considerably more; some lose less. NICE guidance notes that if weight loss is below 5% after six months at the maintenance dose, the decision to continue should be reviewed. Early weeks can feel slow, the body needs time to adjust, and the dose escalation period is not yet at full therapeutic strength. Our Wegovy weight-loss by week breakdown gives a realistic picture of when most people start to notice a difference.

Wegovy works best alongside meaningful changes to diet and activity. The medicine reduces appetite; what you do with that reduced appetite shapes the outcome. Questions about supplements are common at this stage, and if you are wondering whether turmeric is safe to take alongside Wegovy, our dedicated page covers the evidence. It is not a substitute for support, it is a tool that makes the effort more achievable for people whose biology has been working against them.

Storing your pens correctly is also part of getting the most from treatment, and our guide to Wegovy use-by dates and storage explains what to check before each injection. If you are ready to find out whether Wegovy fits your circumstances, check your eligibility with our prescribers, the consultation is free, and there is no commitment to proceed.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions